The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

Ankara Education and Research Hospital100 enrolled

Overview

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Metabolic Diseases Chronic Kidney Disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * between ages of 18 - 65 years old * chronic kidney disease of stage 2-4 Exclusion Criteria: * presence of diabetes mellitus or ischemic hearth disease * taking vitamin d therapy

Locations (1)

Ankara Education and Research Hospital

Ankara, Turkey (Türkiye)

RECRUITING

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.